Human application

Under the Human Tissue (Quality and Safety for Human Application) Regulations 2007 (Q&S Regulations), the HTA licenses and inspects establishments that undertake the procurement, testing, processing, storage, distribution, import and export of tissues and cells for human application.

Add paragraph

Licensed establishments include a wide range of organisations such as hospitals, stem cell laboratories and tissue banks, as well as private companies such as cord blood banks, suppliers of acellular material and establishments that procure the starting material for Advanced Therapy Medicinal Products (ATMPs). Establishments licensed under the Q&S Regulations work with a wide variety of tissue/cell types, including bone, skin, heart valves, bone marrow, stem cells, chondrocytes, and pancreatic islets.

Licensed establishments are required to meet the standards which are detailed in the HTA’s ‘Guide to Quality and Safety Assurance of Human Tissues and Cells for Patient Treatment’ as implemented by Directions 001/2021. These Directions consolidate and clarify the standards required under the Q&S Regulations.

Promotional Card List

Item List

Updated on 14 Apr, 2025

Regulation on standards of quality and safety for substances of human origin intended for human application (SoHO)

This page contains information about the SoHO Regulation, which took effect in the EU in August 2024 and applies to Northern Ireland under the Windsor Framewo...
Updated on 23 Dec, 2024

Annual activity data collection

All establishments licensed to carry out activities under the Human Tissue (Quality and Safety for Human Application) Regulations 2007 must submit data relati...
Updated on 01 Mar, 2022

HTA Guide to Quality and Safety Assurance for Tissues and Cells for Patient Treatment

This guide explains the regulatory requirements for establishments in the Human Application sector. The requirements apply to establishments that store and...
Updated on 11 May, 2023

Human application sector - HTA standards

Human Tissue (Quality and Safety for Human Application) Regulations 2007 (as amended) licensing standards.
Updated on 20 Jul, 2022

Human application serious adverse event and reaction (SAEARs) reporting

Updated on 15 Jul, 2024

Material covered by the Human Tissue (Quality and Safety for Human Application) Regulations 2007

The list below provides guidance on which types of tissues and cells are regulated under the Human Tissue (Quality and Safety for Human Application) Regulatio...
Updated on 01 Mar, 2022

Position statement on the biological tests required for autologous donors of tissues and cells

Issued 17 August 2009 It is a requirement of the Human Tissue (Quality and Safety for Human Application) Regulations 2007 that autologous donor serum testi...
Updated on 01 Mar, 2022

Regenerative medicine and the regulation of advanced therapies medicinal products

Updated on 01 Mar, 2022

The Regulatory Advice Service for Regenerative Medicine (RASRM)

RASRM is a ‘one stop shop’ for research and development professionals across academia, industry, and the NHS. It offers a single point of access to free, clea...
Updated on 16 Nov, 2023

Establishments involved in cord blood collection

The Designated Individual (DI) at the licensed establishment is responsible for ensuring suitable practices take place under the authority of the Human Tissue...
Updated on 01 Mar, 2022

Position on the procurement of tumour material

Guidance for establishments on meeting HTA licensing requirements for the procurement of tumour samples to be used as a starting material in the manufacture o...
Updated on 10 Mar, 2025

HFEA and HTA joint statement on ovarian and testicular tissue storage

The Human Fertilisation and Embryology Authority (HFEA) and the Human Tissue Authority (HTA) have been working together to reduce the regulatory overlap regar...
Updated on 01 Mar, 2022

Clarification of the scope of the Medical Devices Regulation for tissues and cells products

New EU regulations for medical devices (MDR) and in-vitro medical devices (IVDR) have been introduced. These regulations entered into force on 25 May 2017 acr...
Updated on 08 Mar, 2022

Regulating human embryonic stem cell lines for human application

This is the joint position from the Human Tissue Authority (HTA), Human Fertilisation and Embryology Authority (HFEA) and Medicines and Healthcare products Re...
Updated on 01 Mar, 2022

Regulation of faecal microbiota transplant

Faecal microbiota transplantation (FMT) is recognised as an emerging treatment for recurrent Clostridium difficile infections in patients where antibiotic and...
Updated on 01 Mar, 2022

Compliance resource for US Imports

Importing tissue establishments must ensure that imports from third countries meet standards of quality and safety equivalent to those in the UK. The majority...
Updated on 01 Mar, 2022

Third party agreements (TPA)

Information and guidance on third party agreements
Updated on 06 Dec, 2022

Independent audits guidance

The HTA’s HA licensing standard, GQ2c, requires an audit to be conducted in an independent manner at least every two years.
Updated on 01 Mar, 2022

Preparation Process Dossiers guidance

It is a mandatory requirement that the processes used to prepare tissue or cells for patient treatment (human application) do not render them clinically ineff...